Acute Graft versus Host Disease Following Liver Transplantation: The Enemy Within

American Journal of Transplantation

Volumn 4, Issue 4, 2004, Pages 466-474

  Taylor, Anna L ^a   Gibbs, Paul ^a   Bradley, J Andrew ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Graft vs. host disease; Liver transplantation

Indexed keywords

ANTIINFECTIVE AGENT; BASILIXIMAB; CORTICOSTEROID; DACLIZUMAB; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ANTIBODY; KERATINOCYTE GROWTH FACTOR; LIPOPOLYSACCHARIDE; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; OKT 3; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHIMERA; CLINICAL FEATURE; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; INFECTION CONTROL; LIVER TRANSPLANTATION; LYMPHOCYTE; MACROCHIMERISM; NEUTROPENIA; ORGAN DONOR; ORTHOTOPIC TRANSPLANTATION; OUTCOMES RESEARCH; PATHOGENESIS; PERIPHERAL CIRCULATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECIPIENT; RISK FACTOR; SHORT SURVEY;

AGE FACTORS; ANIMALS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MODELS, BIOLOGICAL; PHENOTYPE; RISK FACTORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS;

EID: 1942502277     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00406.x     Document Type: Short Survey

References (74)

1. Triulzi DJ, Shirey RS, Ness PM, Klein AS. Immunohematologic complications of ABO-unmatched liver transplants. Transfusion 1992; 32: 829-33.
2. Burdick JF, Vogelsang GB, Smith WJ et al. Severe graft-versus-host disease in a liver-transplant recipient. N Engl J Med 1988; 318: 689-691.
3. Smith DM, Agura E, Netto G et al. Liver transplant-associated graft-versus-host disease. Transplantation 2003; 75: 118-126.
4. Taylor AL, Sudhindran S, Key T et al. Monitoring systemic donor lymphocyte macrochimerism to aid the differential diagnosis of Graft versus Host disease following liver transplantation. Transplantation 2004; 77: 441-446.
5. Jamieson NV, Joysey V, Friend PJ et al. Graft-versus-host disease in solid organ transplantation. Transpl Int 1991; 4: 67-71.
6. Sudhindran S, Taylor A, Delriviere L et al. Treatment of graft-versus-host disease after liver transplantation with basiliximab followed by bowel resection. Am J Transplant 2003; 3: 1024-1029.
7. Lehner F, Becker T, Sybrecht L et al. Successful outcome of acute graft-versus-host disease in a liver allograft recipient by withdrawal of immunosuppression. Transplantation 2002; 73: 307-310.
8. Rinon M, Maruri N, Arrieta A, Fernandez JR, Ortiz de Urbina J, Garcia Masdevall MD. Selective immunosuppression with daclizumab in liver transplantation with graft-versus-host disease. Transplant Proc 2002; 34: 109-110.
9. Jonsson JR, Hogan PG, Thomas R et al. Peripheral blood chimerism following human liver transplantation. Hepatology 1997; 25: 1233-1236.
10. Joysey VC, Wood H, Ramsbottom S et al. Lymphocyte chimaerism after organ transplantation. Transplant Proc 1992; 24: 2519-2522.
11. Nemoto T, Kubota K, Kita J et al. Unusual onset of chronic graft-versus-host disease after adult living-related liver transplantation from a homozygous donor. Transplantation 2003; 75: 733-736.
12. Redondo P, Espana A, Herrero JI et al. Graft-versus-host disease after liver transplantation. J Am Acad Dermatol 1993; 29: 314-317.
13. Schlitt HJ, Kanehiro H, Raddatz G et al. Persistence of donor lymphocytes in liver allograft recipients. Transplantation 1993; 56: 1001-1007.
14. Burakoff S, Deeg J, Ferrera J, Atkinson K. Graft-vs.-host disease. In: Brinkhous K, Stass S (eds). Haematology. New York, Basel: Marcel Dekker, Inc., 1990.
15. Pinna AD, Weppler D, Berho M et al. Unusual presentation of graft-versus-host disease in pediatric liver transplant recipients: evidence of late and recurrent disease. Pediatr Transplant 1999; 3: 236-242.
16. Dunn SP, Krueger LJ, Butani L, Punnett H. Late onset of severe graft-versus-host disease in a pediatric liver transplant recipient. Transplantation 2001; 71: 1483-1485.
17. Kiuchi T, Harada H, Matsukawa H et al. One-way donor-recipient HLA-matching as a risk factor for graft-versus-host disease in living-related liver transplantation. Transpl Int 1998; 11: S383-S384.
18. Au WY, Ma SK, Kwong YL et al. Graft-versus-host disease after liver transplantation: documentation by fluorescent in situ hybridisation and human leucocyte antigen typing. Clin Transplant 2000; 14: 174-177.
19. Au WY, Lo CM, Hawkins BR, Ma ES, Lie AK, Kwong YL. Evans' syndrome complicating chronic graft versus host disease after cadaveric liver transplantation. Transplantation 2001; 72: 527-528.
20. Schmuth M, Vogel W, Weinlich G, Margreiter R, Fritsch P, Sepp N. Cutaneous lesions as the presenting sign of acute graft-versus-host disease following liver transplantation. Br J Dermatol 1999; 141: 901-904.
21. Whitington PF, Rubin CM, Alonso EM et al. Complete lymphoid chimerism and chronic graft-versus-host disease in an infant recipient of a hepatic allograft from an HLA-homozygous parental living donor. Transplantation 1996; 62: 1516-1519.
22. Billingham RE. The biology of graft-versus-host reactions. Harvey Lectures 1966-67; 62: 21-78.
23. Vogelsang GB, Lee L, Bensen-Kennedy DM. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med 2003; 54: 29-52.
24. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant 1999; 5: 347-356.
25. Jacobsohn DA, Vogelsang GB. Novel pharmacotherapeutic approaches to prevention and treatment of GVHD. Drugs 2002; 62: 879-889.
26. Triulzi DJ, Nalesnik MA. Microchimerism, GVHD, and tolerance in solid organ transplantation. Transfusion 2001; 41: 419-426.
27. Norris S, Collins C, Doherty DG et al. Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. J Hepatol 1998; 28: 84-90.
28. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol 2001; 29: 259-277.
29. De Wit D, Van Mechelen M, Zanin C et al. Preferential activation of Th2 cells in chronic graft-versus-host reaction. J Immunol 1993; 150: 361-366.
30. Via CS, Finkelman FD. Critical role of interleukin-2 in the development of acute graft-versus-host disease. Int Immunol 1993; 5: 565-572.
31. Collins RH Jr, Anastasi J, Terstappen LW et al. Brief report: donor-derived long-term multilineage hematopoiesis in a liver-transplant recipient. N Engl J Med 1993; 328: 762-765.
32. Imamura M, Tsutsumi Y, Miura Y, Toubai T, Tanaka J. Immune reconstitution and tolerance after allogeneic hematopoietic stem cell transplantation. Hematology 2003; 8: 19-26.
33. Parham P, McQueen KL. Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nat Rev Immunol 2003; 3: 108-122.
34. Urbano-Ispizua A, Rozman C, Pimentel P et al. Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. Blood 2002; 100: 724-727.
35. Ordemann R, Hutchinson R, Friedman J et al. Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease. J Clin Invest 2002; 109: 1249-1256.
36. Roberts JP, Ascher NL, Lake J et al. Graft vs. host disease after liver transplantation in humans: a report of four cases. Hepatology 1991; 14: 274-281.
37. Romagnuolo J, Jewell LD, Kneteman NM, Bain VG. Graft-versus-host disease after liver transplantation complicated by systemic aspergillosis with pancarditis. Can J Gastroenterol 2000; 14: 637-640.
38. Bhaduri BR, Tan KC, Humphreys S et al. Graft-versus-host disease after orthotopic liver transplantation in a child. Transplant Proc 1990; 22: 2378-2380.
39. Korngold B, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med 1978; 148: 1687-1698.
40. Lowenberg B, Wagemaker G, van Bekkum DW et al. Graft-versus-host disease following transplantation of 'one log' versus 'two log' T-lymphocyte-depleted bone marrow from HLA-identical donors. Bone Marrow Transplant 1986; 1: 133-140.
41. Goldberg LC, Bradley JA, Connolly J et al. Anti-CD45 monoclonal antibody perfusion of human renal allografts prior to transplantation. A safety and immunohistological study. CD45 Study Group. Transplantation 1995; 59: 1285-1293.
42. Williams JG, Pirenne J, Mayoral JM et al. Effect of donor pretreatment with anti-lymphocyte globulin on small bowel transplantation in rats. Br J Surg 1991; 78: 1176-1177.
43. Shaffer D, Maki T, DeMichele SJ et al. Studies in small bowel transplantation. Prevention of graft-versus-host disease with preservation of allograft function by donor pretreatment with antilymphocyte serum. Transplantation 1988; 45: 262-269.
44. Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M. Cell migration, chimerism, and graft acceptance. Lancet 1992; 339: 1579-1582.
45. Hings IM, Filipovich AH, Miller WJ. Prednisolone therapy for acute graft-vs-host disease: short- vs lont-term treatment. A prospective randomised trial. Transplantation 1993; 56: 577.
46. Martin PJ, Schoch G, Fisher L. A retrospective analysis of therapy for acute graft-vs-host disease: initial treatment. Blood 1990; 76: 1464.
47. Deeg HJ, Loughran TP Jr, Storb R et al. Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. Transplantation 1985; 40: 162-166.
48. Doney KC, Weiden PL, Storb R, Thomas ED. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients. a randomized trial comparing antithymocyte globulin and corticosteroids. Am J Hematol 1981; 11: 1-8.
49. Khoury H, Kashyap A, Adkins DR et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 2001; 27: 1059-1064.
50. McCaul KG, Nevill TJ, Barnett MJ et al. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin. J Hematother Stem Cell Res 2000; 9: 367-374.
51. Remberger M, Aschan J, Barkholt L, Tollemar J, Ringden O. Treatment of severe acute graft-versus-host disease with antithymocyte globulin. Clin Transplant 2001; 15: 147-153.
52. Massenkeil G, Rackwitz S, Genvresse I, Rosen O, Dorken B, Arnold R. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30: 899-903.
53. Przepiorka D, Kernan NA, Ippoliti C et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95: 83-89.
54. Willenbacher W, Basara N, Blau IW, Fauser AA, Kiehl MG. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol 2001; 112: 820-823.
55. Uchiyama T, Broder S, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol 1981; 126: 1393-1397.
56. Uchiyama T, Nelson DL, Fleisher TA, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells. J Immunol 1981; 126: 1398-1403.
57. Kobbe G, Schneider P, Rohr U et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant 2001; 28: 47-49.
58. Jacobsohn DA, Hallick J, Anders V, McMillan S, Morris L, Vogelsang GB. Infliximab for steroid-refractory acute GVHD. A case series. Am J Hematol 2003; 74: 119-124.
59. Deeg HJ. Graft-versus-host disease and the development of late complications. Transfus Sci 1994; 15: 243-254.
60. Miller W, Flynn P, McCullough J et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood 1986; 67: 1162-1167.
61. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478-488.
62. Tamada K, Tamura H, Flies D et al. Blockade of LIGHT/LTbeta and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. J Clin Invest 2002; 109: 549-557.
63. Via CS, Rus V, Nguyen P, Linsley P, Gause WC. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD. J Immunol 1996; 157: 4258-4267.
64. Cooke KR, Gerbitz A, Crawford JM et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 2001; 107: 1581-1589.
65. Williamson E, Garside P, Bradley JA, More IA, Mowat AM. Neutralizing IL-12 during induction of murine acute graft-versus-host disease polarizes the cytokine profile toward a Th2-type alloimmune response and confers long term protection from disease. J Immunol 1997; 159: 1208-1215.
66. Clouthier SG, Cooke KR, Teshima T et al. Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect. Biol Blood Marrow Transplant 2003; 9: 592-603.
67. Mazzaferro V, Andreola S, Regalia E et al. Confirmation of graft-versus-host disease after liver transplantation by PCR HLA-typing. Transplantation 1993; 55: 423-425.
68. Sanchez-Izquierdo JA, Lumbreras C, Colina F et al. Severe graft versus host disease following liver transplantation confirmed by PCR-HLA-B sequencing: report of a case and literature review. Hepatogastroenterology 1996; 43: 1057-1061.
69. Pageaux GP, Perrigault PF, Fabre JM et al. Lethal acute graft-versus-host disease in a liver transplant recipient: relations with cell migration and chimerism. Clin Transplant 1995; 9: 65-69.
70. Joseph JM, Mosimann F, Tiercy JM et al. PCR confirmation of microchimerism and diagnosis of graft versus host disease after liver transplantation. Transpl Int 1999; 12: 468-470.
71. Rosen CB, Ng CS, Moore SB et al. Clinical and pathological features of graft-versus-host disease after liver transplantation: a case report and review of the literature. Clin Transplant 1993; 7: 52-58.
72. DePaoli AM, Bitran J. Graft-versus-host disease and liver transplantation. Ann Intern Med 1992; 117: 170-171.
73. Marubayashi S, Matsuzaka C, Takeda A et al. Fatal generalized acute graft-versus-host disease in a liver transplant recipient. Transplantation 1990; 50: 709-711.
74. Neumann UP, Kaisers U, Langrehr JM et al. Fatal graft-versus-host-disease: a grave complication after orthotopic liver transplantation. Transplant Proc 1994; 26: 3616-3617.